Zhitong Finance App News, Junshi Biotech (01877.HK) issued an announcement. Recently, the company received the “Notice of Acceptance” approved and issued by the State Drug Administration. The application for marketing of the company's product treprilizumab injection (subcutaneous injection) (code: js001sc) and verdicitumab for HER2 expression (HER2 expression is defined as HER2 immunohistochemical test results are 1+, 2+ or 3+) for locally advanced or metastatic urothelial carcinoma was accepted. Triplimab injection (subcutaneous injection) The marketing applications for all 13 approved indications of treprilimab injection (trade name: Tuoyi®, code: JS001) have been accepted.
Zhitongcaijing · 2d ago
Share
Listen to the news
Zhitong Finance App News, Junshi Biotech (01877.HK) issued an announcement. Recently, the company received the “Notice of Acceptance” approved and issued by the State Drug Administration. The application for marketing of the company's product treprilizumab injection (subcutaneous injection) (code: js001sc) and verdicitumab for HER2 expression (HER2 expression is defined as HER2 immunohistochemical test results are 1+, 2+ or 3+) for locally advanced or metastatic urothelial carcinoma was accepted. Triplimab injection (subcutaneous injection) The marketing applications for all 13 approved indications of treprilimab injection (trade name: Tuoyi®, code: JS001) have been accepted.
Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.
What's Trending